Table 3.
Association of serum uromodulin with ESKD, cardiovascular events and all-cause mortality
| Serum uromodulin tertiles (ng/mL) | Model 1 | Model 2 | Model 3 |
|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |
| ESKD events | |||
| > 100.8 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| > 52.7–100.8 | 3.70 (2.48, 5.54) | 3.23 (2.15, 4.85) | 1.36 (0.90, 2.06) |
| ≤ 52.7 | 10.46 (7.20, 15.21) | 7.47 (5.06, 11.03) | 1.92 (1.26, 2.90) |
| Per SD increase | 0.26 (0.21, 0.32) | 0.31 (0.25, 0.38) | 0.69 (0.55, 0.86) |
| Cardiovascular events | |||
| > 100.8 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| > 52.7–100.8 | 1.37 (0.92, 2.04) | 1.04 (0.70, 1.56) | 0.80 (0.52, 1.22) |
| ≤ 52.7 | 1.85 (1.27, 2.70) | 1.24 (0.83, 1.86) | 0.81 (0.51, 1.28) |
| Per SD increase | 0.71 (0.59, 0.87) | 0.88 (0.72, 1.08) | 1.14 (0.89, 1.45) |
| All-cause mortality | |||
| > 100.8 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| > 52.7–100.8 | 1.63 (0.80, 3.29) | 1.35 (0.65, 2.77) | 1.04 (0.48, 2.23) |
| ≤ 52.7 | 2.59 (1.34, 5.00) | 1.94 (0.96, 3.94) | 1.30 (0.58, 2.93) |
| Per SD increase | 0.63 (0.45, 0.89) | 0.73 (0.51, 1.04) | 0.92 (0.60, 1.41) |
Model 1: Adjusted for age, gender
Model 2: Model 1+ current smoker, body-mass index, diabetes, systolic blood pressure, using anti-hypertensive medications in the past 2 weeks, cardiovascular diseases history, logarithm transformed triglyceride, logarithm transformed low-density lipoprotein cholesterol, prealbumin, logarithm transformed high-density lipoprotein cholesterol, logarithm transformed sensitive-reactive protein and logarithm transformed urinary albumin/creatinine ratio
Model 3: Model 2+ estimated glomerular filtration rate
ESKD end stage kidney disease, SD standard deviation